Brown J M, Greager J A, Pavel D G, Gupta T K
J Natl Cancer Inst. 1985 Oct;75(4):637-44.
125I-labeled monoclonal antibody 19-24 (mouse isotype IgG1) was evaluated for its potential usefulness in the clinical radioimmunodetection of sarcoma. The antibody reacts with a cell surface antigen preferentially expressed in many human soft tissue and bone sarcomas. Chromatographic and electrophoretic analyses indicated that the labeled preparation was relatively pure. Binding studies in vitro demonstrated that specificity for antigen was retained after iodination and indicated that the labeled antibody possessed an immunoreactivity in excess of 90% and a binding constant of 8.1 X 10(9) M-1. When administered to athymic NCr-nu/nu mice bearing 1-cm diameter human fibrosarcoma HT-1080 xenografts, the labeled antibody preferentially localized in tumor deposits. Maximum tumor-to-blood radioactivity ratios (2.2-3.4) were obtained 7 days after antibody injection. Specificity of the localization was confirmed with a control mouse IgG1 antibody and by using a nonreactive xenograft. Distinct tumor images were obtained by gamma camera without the use of subtraction techniques, demonstrating the possible clinical utility of the labeled antibody.
对125I标记的单克隆抗体19 - 24(小鼠同型IgG1)在肉瘤临床放射免疫检测中的潜在用途进行了评估。该抗体与一种在许多人类软组织和骨肉瘤中优先表达的细胞表面抗原发生反应。色谱和电泳分析表明,标记制剂相对纯净。体外结合研究表明,碘化后抗原特异性得以保留,且标记抗体的免疫反应性超过90%,结合常数为8.1×10⁹ M⁻¹。当将其给予携带直径1厘米人纤维肉瘤HT - 1080异种移植物的无胸腺NCr - nu/nu小鼠时,标记抗体优先定位于肿瘤沉积物中。抗体注射7天后获得最大肿瘤与血液放射性比值(2.2 - 3.4)。用对照小鼠IgG1抗体并通过使用无反应性异种移植物证实了定位的特异性。通过γ相机无需使用减法技术即可获得清晰的肿瘤图像,证明了标记抗体可能的临床应用价值。